The latest price target for GT Biopharma (NASDAQ:GTBP) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $5.00 expecting GTBP to rise to within 12 months (a possible 67.79% upside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for GT Biopharma (NASDAQ:GTBP) was provided by HC Wainwright & Co., and GT Biopharma reiterated their buy rating.

There is no last upgrade for GT Biopharma

There is no last downgrade for GT Biopharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GT Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GT Biopharma was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.

While ratings are subjective and will change, the latest GT Biopharma (GTBP) rating was a reiterated with a price target of $0.00 to $5.00. The current price GT Biopharma (GTBP) is trading at is $2.98, which is within the analyst’s predicted range.